- Home
- GBLI vs ZURA Comparison
GBLI vs ZURA Comparison
Compare GBLI & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GBLI | ZURA |
|---|---|---|
| Founded | 2016 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 398.7M | 455.4M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GBLI | ZURA |
|---|---|---|
| Price | $28.60 | $6.15 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 3.0K | ★ 1.2M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $450,098,000.00 | N/A |
| Revenue This Year | $14.23 | N/A |
| Revenue Next Year | $9.68 | N/A |
| P/E Ratio | $27.24 | ★ N/A |
| Revenue Growth | ★ 2.02 | N/A |
| 52 Week Low | $24.28 | $1.88 |
| 52 Week High | $30.52 | $7.25 |
Technical Indicators
Market Signals| Indicator | GBLI | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 58.90 | 61.13 |
| Support Level | $27.66 | $5.22 |
| Resistance Level | $29.16 | $6.65 |
| Average True Range (ATR) | 0.89 | 0.36 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 89.07 | 44.89 |
Price Performance
Historical ComparisonAbout GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC is a United States-based holding company with a diversified portfolio of property and casualty insurance-related entities. Along with its subsidiaries, the company operates in the following reportable segments: Agency and Insurance Services, Belmont Insurance Companies - Core (Belmont Core), and Belmont Insurance Companies - Non-Core (Belmont Non-Core). Maximum revenue is generated from the Belmont Core segment, which offers direct insurance and assumed reinsurance products in the E&S (Excess and Surplus) marketplace. The Agency and Insurance Services segment is focused on sourcing, underwriting, and servicing primary and assumed reinsurance business; and specialized insurance service businesses providing technology, AI-enabled marketplace, and claims services.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.